The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines

In Vivo

Volumn 28, Issue 5, 2014, Pages 843-850

  Pawlak, Aleksandra ^a   Rapak, Andrzej ^b   Zbyryt, Iwona ^a   Obmińska Mrukowicz, Bozena ^a  

^a WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Apoptosis; Canine leukemia; Canine lymphoma; Cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; LOMUSTINE; PREDNISONE; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; B CELL LEUKEMIA; CANINE LEUKEMIA; CANINE LYMPHOMA; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DNA FRAGMENTATION; DOG DISEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; FLOW CYTOMETRY; IC50; JURKAT CELL LINE; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MITOSIS SPINDLE; MTT ASSAY; NONHUMAN; PHENOTYPE; STAINING; ANIMAL; CELL SURVIVAL; DOG; DRUG EFFECTS; LEUKEMIA; LYMPHOMA; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DOGS; FLOW CYTOMETRY; INHIBITORY CONCENTRATION 50; LEUKEMIA; LYMPHOMA;

EID: 84918505335     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Breen M and Modiano JF: Evolutionary conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his Best friend share more than companionship. Chrom Res 16: 145-54, 2008.
2. Kisseberth WC, Nadella MV, Breen M, Thomas R, Duke SE, Murahari S, Kosarek CE, Vernau W, Avery AC, Burkhard MJ and Rosol TJ: A novel canine lymphoma cell line: A translational and comparative model for lymphoma research. Leuk Res 31: 1709-1720, 2007.
3. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C and Tedesco F: An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of Bcell malignancies. Curr Pharm Design 14: 2023-2039, 2008.
4. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S and Withrow S: The dog as a cancer model. Nat Biotech 24: 1065-1066, 2006.
5. Abramowicz B, Lutnicki K, Łopuszyński W and Szpringer E: Lymphoma in a dog - practical aspects of diagnosis. Med Weter 66: 635-639, 2010 (in Polish).
6. Seiser EL, Thomas R, Richards KL, Kelley MK, Moore P, Suter SE and Breen M: Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines. Vet Comp Oncol 11: 30-50, 2011.
7. Nakaichi M, Taura Y, Kanki M, Mamba K, Tsujimoto H and Nakama S: Establishment and characterization of a new canine B-cell leukemia cell Line. J Vet Med Sci 58: 469-471, 1996.
8. Momoi Y, Okai Y, Watari T, Giotsuka R, Tsujimoto H and Hasegawa A: Establishment and characterization of a canine Tlymphoblastoid cell line derived from malignant lymphoma. Vet Immunol Immunopatol 59: 11-20, 1997.
9. Ruetgen BC, Hammer SE, Gerner W, Christian M, Arespacochaga AG, Willmann M, Kleiter M, Schwendenwein I and Saalmuller A: Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk 34: 932-938, 2010.
10. Ghernati I, Auger C, Chabanne L, Corbin A, Bonnefont C, Magnol J, Fournel C, Rivoire A, Monir JC and Rigal D: Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sezary syndrome and producing retroviral particles. Leuk 13: 1281-1290, 1999.
11. Ghernati I, Corbin A, Chabanne L, Auger C, Magnol JP, Fournel C, Monier JC, Darlix JL and Rigal D: Canine large granular lymphocyte leukemia and its derived cell line produce infectious retroviral particles. Vet Pathol 37: 310-317, 2000.
12. Umeki S, Ema Y, Suzuki R, Kubo M, Hayashi T, Okamura Y, Yamazaki J, Tsjimoto H, Tani K, Hiraoka H, Okuda M and Mizuno T: Establishment of Five Canine Lymphoma Cell Lines and Tumor Formation in a Xenotransplantation Model. J Vet Med Sci 75: 467-474, 2013.
13. Matsuda A, Tanaka A, Muto S, Ohmori K, Furusaka T, Jung K, Karasawa K, Okamoto N, Oida K, Rai A and Matsuda H: A novel NFkB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res Vet Sci 89: 378-382, 2010.
14. Matassov D, Kagan T, Leblanc J, Sikorska M and Zakeri Z: Measurement of apoptosis by DNA fragmentation. Methods Mol Biol 282: 1-17, 2004.
15. Hojka-Osinska A, Ziolo E and Rapak A: Combined treatment with fenretinide and indomethacin induces AIF-mediated, nonclassical cell death in human acute T-cell leukemia Jurkat cells. Biochem Biophys Res Comm 419: 590-595, 2012.
16. Marconato L, Gelain ME and Comazzi S: The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 31: 1-9, 2013.
17. Vail DM and MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-92, 2000.
18. Wilkerson MJ, Dolce K, Koopman T, Shuman W, Chun R, Garrett L, Barber L and Avery A: Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Vet Immunol Immunopathol 106: 179-196, 2005.
19. Price GS, Page RL, Fischer BM, Levine JF and Gerig TM: Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Int Med 5: 259-262, 1991.
20. Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ and Mason NJ: NEMO-Binding Domain Peptide Inhibits Constitutive NF- κB Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma. Clin Can Res 17: 4661-4671, 2011.
21. Simon D, Nolte I, Eberle N, Abbrederis N, Killich M and Hirschberger J: Treatment of dogs with lymphoma using a 12- week, maintenance-free combination chemotherapy protocol. J Vet Int Med 20: 948-954, 2006.